This article is more than 5 years old. Information may no longer be current.

Tarsius Pharma receives 2.4 million euro grant

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tarsius Pharma has been awarded a 2.4 million euro Horizon 2020 Grant from the European Commission to support a clinical trial of TRS01, the company’s bioinspired technology, according to a press release.

TRS01 is a new molecule developed to approach autoimmune and inflammatory ocular diseases by “re-engineering” the immune system, the release said.

“We are delighted to be awarded the Horizon 2020 Grant, which validates the need for a viable solution where other approaches have been unsuccessful in treating this patient population,” Daphne Haim-Langford, PhD, founder and CEO of Tarsius Pharma, said in the release. “With this funding, we look forward to launch the clinical development program of Tarsius platform technology. We believe that our treatment approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving their sight.”